Trial Profile
A Phase 1 study of anti-human EGFR (Vectibix sequence) targeted EDVs carrying cytotoxic drug, siRNA or miRNA (VEDVsPayload) in Patients with Advanced Solid Tumours who have no curative treatment options.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2017
Price :
$35
*
At a glance
- Drugs MicroRNAs (Primary) ; Small interfering RNA (Primary) ; Doxorubicin; Gemcitabine; Maytansinoids; Mitoxantrone
- Indications Solid tumours
- Focus Therapeutic Use
- Acronyms Tailored EDV
- Sponsors EnGeneIC
- 03 Oct 2017 New trial record